Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apogee Technology has reported the completion of in vivo proof-of-concept studies and the filing of a new US patent application relating to its intradermal drug delivery technology.
Subscribe to our email newsletter
The patent application encompasses formulations and compounds that can be instrumental in the development of efficient intradermal vaccines.
Alexander Andrianov, Apogee’s vice president of R&D, said: “The new patent application is filed on the basis of findings obtained in our in vivo proof-of-concept studies. The patent application is designed to protect formulations and compounds capable of improving both the device production technology and the efficacy of intradermal vaccines.”